Prehabilitation to Patients With Prostate Cancer
Prehabilitation to Patients With Prostate Cancer, Who Are About to Receive Androgen Deprivation Therapy and Radiation Therapy
Odense University Hospital
20 participants
Aug 4, 2025
INTERVENTIONAL
Conditions
Summary
The goal of this feasibility study is to test a newly developed, multicomponent prehabilitation intervention to patients with prostate cancer, to improve their resilience to treatment side-effects. The main questions it aims to answer are: * Are patients and their close relatives willing to take part in prehabilitation? * What is the acceptability and feasibility of the prehabilitation intervention, seen from the perspectives of patients, their close relatives, and healthcare professionals? * Are the planned data collection methods feasible, and are there indications of a clinical effect? Participants will: * Take part in 12 weeks of physical exercise training * Attend a 4-day residential prehabilitation intervention, where they receive education and do exercises. After 12 weeks, it is possible to take part in a voluntary follow-up session. * Patients will respond to questionnaires about their health, symptoms, and quality of life. Patients and their close relatives will attend a group interview. Patients will also complete an exercise diary and brief physical tests
Eligibility
Inclusion Criteria9
- Diagnosed with prostate cancer
- min 18 years old
- Treatment: Androgen deprivation therapy and raditation therapy
- Resident in Vejle Municipality or Esbjerg Municipality
- Can take part in residential prehabiliation in week 43 or 50, 2025, as well as physical exsercise training in the municipality
- Willing to take part in a research study
- Suited to take part in group sessions
- Be able to read and be understood in Danish
- Be responsible for own personal hygiene and medications at the 4-day residential stay
Interventions
Please refer to arm description
Locations(3)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07162987